Screener
Arbutus Biopharma Corporation ABUS Total Revenue
Total Revenue at other companies
Segments
Other financials
Where this comes from
Reported directly by Arbutus Biopharma Corporation in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The source filing: Arbutus Biopharma Corporation’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 7:31 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001447028-26-000021
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Collaborations and licenses | $204 | $1,316 |
| License revenue from Genevant | 178,741 | — |
| Non-cash royalty revenue | 181 | 448 |
| Total revenue | 179,126 | 1,764 |
| Operating expenses | ||
| Research and development | 4,120 | 8,959 |
| General and administrative | 5,889 | 5,832 |
| Change in fair value of contingent consideration | 209 | 299 |
ITEM 1. FINANCIAL STATEMENTS (UNAUDITED)
FAQ
- What is Arbutus Biopharma Corporation's total revenue?
- Arbutus Biopharma Corporation (ABUS) reported total revenue of $179.13M in Q1 2026.
- How has Arbutus Biopharma Corporation's total revenue changed year-over-year?
- Arbutus Biopharma Corporation's total revenue increased by 10054.5% year-over-year, from $1.76M to $179.13M.
- What is the long-term trend for Arbutus Biopharma Corporation's total revenue?
- Over 4 years (2021 to 2025), Arbutus Biopharma Corporation's total revenue has grown at a 6.4% compound annual growth rate (CAGR), from $10.99M to $14.08M.
- What does total revenue mean?
- The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.
Ask your AI about Arbutus Biopharma Corporation's total revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude